The Medicines for Human Use (Clinical Trials) Regulations 2004
Typestatutory instrumentDate31 Mar 2004Articles342Versions held34Cited by89 documentsLast changed28 Apr 2026
- 11Interpretation of Part 3
- 11aDefinition of notifiable trial
- 11bDefinition of Route B substantial modification
- 12Requirement for authorisation and ethics committee opinion
- 13Supply of investigational medicinal products for the purpose of clinical trials
- 14Request for authorisation to conduct a clinical trial
- 15Application for ethics committee opinion
- 16Request for approval and combined procedure
- 17Assessment of request for approval
- 18Approval procedure for clinical trials
- 18aRequest for further information regarding a request for approval
- 18bApproval procedure for amended requests for approval
- 18cApproval procedure time periods in special circumstances
- 19Clinical trials conducted in countries other than the United Kingdom
- 20Modifications to clinical trial approval
- 21Modifications by the licensing authority or the ethics committee
- 22Modifications by the sponsor
- 22aApproval procedure for substantial modifications
- 22bRequest for further information regarding proposed substantial modifications
- 22cApproval procedure for amended requests regarding substantial modifications
- 23Reference to the appropriate committee or the Medicines Commission
- 24Review and appeal relating to ethics committee opinion
- 25Transparency requirements
- 26Lapse of clinical trial approval
- 27Conclusion of clinical trial
- 27aInformation sharing
- 27bPublication of information
- 36Requirement for authorisation to manufacture or import investigational medicinal products
- 36aManufacture of MM investigational medicinal products
- 36bManufacture of POC investigational medicinal products
- 37Exemption for hospitals and health centres
- 37aExemption for radiopharmaceuticals used for diagnostic purposes
- 38Application for manufacturing authorisation
- 39Consideration of application for manufacturing authorisation
- 40Grant or refusal of manufacturing authorisation
- 41Application and effect of manufacturing authorisation
- 42Obligations of manufacturing authorisation holder
- 43Qualified persons
- 43aApproved country for import
- 44Variation of manufacturing authorisation
- 44aVariation of MM (IMP) master file
- 44bVariation of POC (IMP) master file
- 45Suspension and revocation of manufacturing authorisation
- 1List of countries for the purpose of the definition of “marketing authorization” on IP completion day (regul
- 2List of countries where a sponsor of a clinical trial, or their legal representative, may be established on
- 3Import of investigational medicinal products into Great Britain from EEA States during the transitional peri
- 4Approved country for import list on IP completion day (regulation 43A)
- 1Interpretation
- 2Application of the old rules to the authorisation etc of existing clinical trials
- 3Application of Good Clinical Practice to old rules clinical trials
- 4Pharmacovigilance in respect of old rules clinical trials
- 5Manufacture and importation of investigational medicinal products used in old rules clinical trials
- 6Labelling of investigational medicinal products used in old rules clinical trials
- 7Enforcement etc
Source: legislation.gov.uk (The National Archives), UK legislation with its point-in-time versions. Official publication. Reuse: Open Government Licence v3.0.